Achieving depletion of regulatory T cells while sparing tumor-specific effector T cells has long remained an elusive goal of immunotherapy. A new study describing the development of an antibody to the cytokine receptor CD25 optimized to ensure depletion of regulatory T cells without blocking binding of the cytokine IL-2 will reinvigorate interest in this therapeutic avenue.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer
Translational Medicine Communications Open Access 19 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. J. Immunol. 155, 1151–1164 (1995).
Onizuka, S. et al. Cancer Res. 59, 3128–3133 (1999).
Woo, E. Y. et al. J. Immunol. 168, 4272–4276 (2002).
Shang, B., Liu, Y., Jiang, S. J. & Liu, Y. Sci. Rep. 5, 15179 (2015).
Solomon, I. et al. Nat. Cancer https://doi.org/10.1038/s43018-020-00133-0 (2020).
Jacobs, J. F. et al. Clin. Cancer Res. 16, 5067–5078 (2010).
Rech, A. J. et al. Sci. Transl. Med. 4, 134ra162 (2012).
Thornton, A. M. & Shevach, E. M. J. Exp. Med. 188, 287–296 (1998).
Arce Vargas, F. et al. Immunity 46, 577–586 (2017).
van Elsas, A., Hurwitz, A. A. & Allison, J. P. J. Exp. Med. 190, 355–366 (1999).
Suntharalingam, G. et al. N. Engl. J. Med. 355, 1018–1028 (2006).
Loskog, A. et al. Leukemia 20, 1819–1828 (2006).
Rafiq, S. et al. Nat. Biotechnol. 36, 847–856 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Ellis, G.I., Riley, J.L. How to kill Treg cells for immunotherapy. Nat Cancer 1, 1134–1135 (2020). https://doi.org/10.1038/s43018-020-00155-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-020-00155-8
This article is cited by
-
iMN041 is an immunotherapeutic and an effective treatment in mouse xenograft models of pancreatic cancer, renal cancer and triple negative breast cancer
Translational Medicine Communications (2024)
-
PLEK2 and IFI6, representing mesenchymal and immune-suppressive microenvironment, predicts resistance to neoadjuvant immunotherapy in esophageal squamous cell carcinoma
Cancer Immunology, Immunotherapy (2023)